ArticleEJHaem2026
Transcranial Doppler Ultrasound Velocity Measurements in Children With Sickle Cell Disease in Kenya.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sickle cell disease (SCD) is the most common inherited haemoglobinopathy and poses a high public health burden in Sub-Saharan Africa. Children with sickle cell anaemia are at a highrisk of ischemic stroke, and transcranial Doppler (TCD) ultrasonography helps identify those at highest risk for primary stroke prevention. Objective: To determine the prevalence of abnormal cerebral blood flow velocity (CBFV) in children with SCD and describe CBFV in children without SCD. Methods: We conducted a two-component study comprising a retrospective review and a cross-sectional assessment. TCD measurements from 143 children with confirmed SCD aged 2-16 years were reviewed. In a cross-sectional arm, children without SCD aged 3-11 years ( Results: Among 143 children screened, all of whom were receiving hydroxyurea, 1.4% had high TCD velocities (≥ 200 cm/s), while 4.9% had low velocities (< 50 cm/s). TCD velocities were not associated with demographic/clinical characteristics or haemoglobin levels. Symmetric MCA flows with wide depth and velocity range variability were observed. In children without SCD, all MCA velocities were within the normal range (50-149 cm/s), showed right-left symmetry, declined with age, and were broadly similar by gender. Conclusion: The prevalence of abnormal TCD velocities was low in children with SCD receiving universal hydroxyurea. In children without SCD, MCA velocities were normal and declined with age, providing local reference values. The observed variability in CBFV supports continued annual TCD screening and repeat scans to confirm stroke-risk classification. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.